Table 4.

Polymeric micelle-based formulations containing chemotherapeutic drugs in clinical trials.

Formulation Trade Name	Incorporated Drug	Purpose	Polymer	Particle Size (nm)	Drug Loading (%)	Phase	References
Genexol-PM	Paclitaxel	Solubilization	MPEG-PDLLA	<50	16.7	III, IV	[127]
NK-105	Paclitaxel	Targeting	PEG-P(Asp)	85	23.0	II, III	[128]
SP-1049C	Doxorubicin	Anti-MDR effect	Pluronic L61, F127	30	8.2	I, II, III	[69]
DTXL-TNP	Doxorubicin	Targeting	PLA-PEG, PLA-PEG-ACUPA	100	10	I	[129]
NC-6004	Cisplatin	Targeting	PEG-P(Glu)-Cisplatin	30	39	I, II	[130]
NC-4016	DACH-platin	Targeting	PEG-P(Glu)-DACH-platin	20–100	25	I	[131]
NK 012	SN-38	Targeting	PEG-P(Glu)-SN38	20	20.0	II	[132]
NK911	Doxorubicin	Targeting	PEG-(Asp)-Dox	40	n. a	II	[133]